- Home
- RUBI vs KZIA Comparison
RUBI vs KZIA Comparison
Compare RUBI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUBI
- KZIA
- Stock Information
- Founded
- RUBI N/A
- KZIA 1994
- Country
- RUBI Marshall Islands
- KZIA Australia
- Employees
- RUBI N/A
- KZIA N/A
- Industry
- RUBI Marine Transportation
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- RUBI Consumer Discretionary
- KZIA Health Care
- Exchange
- RUBI Nasdaq
- KZIA Nasdaq
- Market Cap
- RUBI 10.9M
- KZIA 11.7M
- IPO Year
- RUBI N/A
- KZIA 1999
- Fundamental
- Price
- RUBI $2.70
- KZIA $8.17
- Analyst Decision
- RUBI
- KZIA Strong Buy
- Analyst Count
- RUBI 0
- KZIA 2
- Target Price
- RUBI N/A
- KZIA $14.00
- AVG Volume (30 Days)
- RUBI 1.5M
- KZIA 75.5K
- Earning Date
- RUBI 01-01-0001
- KZIA 08-19-2025
- Dividend Yield
- RUBI N/A
- KZIA N/A
- EPS Growth
- RUBI N/A
- KZIA N/A
- EPS
- RUBI N/A
- KZIA N/A
- Revenue
- RUBI N/A
- KZIA $1,549,158.00
- Revenue This Year
- RUBI N/A
- KZIA N/A
- Revenue Next Year
- RUBI N/A
- KZIA $49.25
- P/E Ratio
- RUBI N/A
- KZIA N/A
- Revenue Growth
- RUBI N/A
- KZIA 248983.08
- 52 Week Low
- RUBI $2.36
- KZIA $2.86
- 52 Week High
- RUBI $6.69
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- RUBI N/A
- KZIA 46.19
- Support Level
- RUBI N/A
- KZIA $7.40
- Resistance Level
- RUBI N/A
- KZIA $8.99
- Average True Range (ATR)
- RUBI 0.00
- KZIA 0.64
- MACD
- RUBI 0.00
- KZIA -0.23
- Stochastic Oscillator
- RUBI 0.00
- KZIA 25.93
About RUBI Rubico Inc. Common Stock
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.